$KMDA News
Last published 2d ago
- 2d agoKMDAKamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027GlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and nine months ended September 30, 2026, an increase o ...
- 2d agoKMDAKamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027GlobeNewswireRecord-Breaking Nine-Month Results: Record High Nine-Month Revenues of $152.2 Million, up 12% Year-over-Year; and Record High Nine-Month Adjusted EBITDA of $40.9 Million, a 27% Margin of Revenues, up 20%
- 2d agoKMDAKamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High YearGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1w agoKMDAKamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026GlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 3w agoKMDAKamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026GlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1mo agoKMDACDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased DemandGlobeNewswireU.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies
- 2mo agoKMDAKamada to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 2mo agoKMDAKamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to ShareholdersGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the "Company") (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products
- 2mo agoKMDAKamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026GlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 3mo agoKMDAKamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual GuidanceGlobeNewswireRecord-High First Half Revenues of $100.2 Million, up 13% Year-over-Year; Record-High First Half Adjusted EBITDA of $25.7 Million, a 26% margin of Revenues, up 14% Year-over-YearRecord-High Second Quarter Revenues of
- 3mo agoKMDAKamada Announces Planned Transition of Chief Financial OfficerGlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 3mo agoKMDAKamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026GlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 3mo agoKMDAKamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived TherapiesGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 4mo agoKMDAKamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual MeetingGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 5mo agoKMDAKamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing LaboratoryGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 6mo agoKMDAKamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the YearGlobeNewswireQ1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues; Net Income of $4.1 Million, up 4% Year-over-YearUnderlying Demand for the Company's
- 6mo agoKMDAKamada to Announce First Quarter 2026 Financial Results on May 13, 2026GlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 7mo agoKMDAKamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to ShareholdersGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the "Company") (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for
- 7mo agoKMDAKamada Announces FDA Approval of its Plasma Collection Center in San Antonio, TexasGlobeNewswireSan Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue
- 8mo agoKMDAKamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026GlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 9mo agoKMDAHow to Successfully Fill Out an HDA Product Form - KAMADA LTDEarnings Call TranscriptsHello, everyone. The Healthcare Distribution Alliance is pleased to continue our educational commitment by bringing you this instructional webinar, How to Successfully Fill Out an HDA Product Form. My name is Marissa Bra
- 10mo agoKMDAKamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial GuidanceGlobeNewswire2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance is Based Solely on Continued Organic GrowthCompany Continues
- 10mo agoKMDAKamada Announces a $10-$14 Million Extension of Canadian Supply TenderGlobeNewswireCompany Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived ProductsSupply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period
- 11mo agoKMDAKamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026GlobeNewswireBased on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its
- 1y agoKMDAKamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability GrowthGlobeNewswireThird Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up
- 1y agoKMDAKamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney TransplantationGlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1y agoKMDAKamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025GlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for
- 1y agoKMDAKamada to Present at the Stifel 2025 Healthcare ConferenceGlobeNewswireREHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1y agoKMDAKamada to Participate in Upcoming September Investor ConferencesGlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1y agoKMDAKamada Ltd. (KMDA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoKMDAKamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability GuidanceGlobeNewswireFirst Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half 2025 Adjusted EBITDA of $22.5 Million, up 35%
- 1y agoKMDAKamada Announces FDA Approval of its Plasma Collection Center in Houston, TexasGlobeNewswireHouston Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of
- 1y agoKMDAKamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025GlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for
- 1y agoKMDAKamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle EastGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1y agoKMDAKamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in ProfitabilityGlobeNewswireRevenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through
- 1y agoKMDAKamada to Announce First Quarter 2025 Financial Results on May 14, 2025GlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for
- 1y agoKMDAKamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®GlobeNewswireProgram Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with
- 1y agoKMDAKamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to ShareholdersGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1y agoKMDAKamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, TexasGlobeNewswireNew Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-DSpecialty
- 1y agoKMDAKamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable GrowthGlobeNewswireRecord Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of RevenuesCash Provided by
- 1y agoKMDAKamada Declares Special Cash Dividend of $0.20 Per ShareGlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for
- 1y agoKMDAKamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025GlobeNewswireREHOVOT, Israel, and HOBOKEN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for
- 1y agoKMDAKamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin AmericaGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 1y agoKMDAKamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025GlobeNewswire• Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024
- 1y agoKMDAKamada Ltd. (KMDA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoKMDAKamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability GuidanceGlobeNewswireRevenues for Third Quarter of 2024 were $41.7 Million, up 10% Year-over-Year; Nine Month 2024 Total Revenues were $121.9 Million, up 15% Year-over-YearThird Quarter 2024 Adjusted EBITDA of $8.8 Million, Representing an
- 2y agoKMDAKamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024GlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 2y agoKMDAKamada to Present at the Stifel 2024 Healthcare ConferenceGlobeNewswireREHOVOT, Israel and HOBOKEN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious
- 2y agoKMDAKamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in HoustonGlobeNewswireNew Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,000 Liters and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full
- 2y agoKMDAKamada Ltd. (KMDA) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts